{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:32:09Z","timestamp":1792740729180,"version":"4.5.0"},"reference-count":51,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T00:00:00Z","timestamp":1520899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T00:00:00Z","timestamp":1525219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["mBio"],"published-print":{"date-parts":[[2018,5,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Bivalent rLP2086 (Trumenba), a vaccine for prevention of\n            <jats:italic>Neisseria meningitidis<\/jats:italic>\n            serogroup B (NmB) disease, was licensed for use in adolescents and young adults after it was demonstrated that it elicits antibodies that initiate complement-mediated killing of invasive NmB isolates in a serum bactericidal assay with human complement (hSBA). The vaccine consists of two factor H binding proteins (fHBPs) representing divergent subfamilies to ensure broad coverage. Although it is the surrogate of efficacy, an hSBA is not suitable for testing large numbers of strains in local laboratories. Previously, an association between the\n            <jats:italic>in vitro<\/jats:italic>\n            fHBP surface expression level and the susceptibility of NmB isolates to killing was observed. Therefore, a flow cytometric meningococcal antigen surface expression (MEASURE) assay was developed and validated by using an antibody that binds to all fHBP variants from both fHBP subfamilies and accurately quantitates the level of fHBP expressed on the cell surface of NmB isolates with mean fluorescence intensity as the readout. Two collections of invasive NmB isolates (\n            <jats:italic>n<\/jats:italic>\n            = 1,814,\n            <jats:italic>n<\/jats:italic>\n            = 109) were evaluated in the assay, with the smaller set also tested in hSBAs using individual and pooled human serum samples from young adults vaccinated with bivalent rLP2086. From these data, an analysis based on fHBP variant prevalence in the larger 1,814-isolate set showed that &gt;91% of all meningococcal serogroup B isolates expressed sufficient levels of fHBP to be susceptible to bactericidal killing by vaccine-induced antibodies.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>IMPORTANCE<\/jats:bold>\n            Bivalent rLP2086 (Trumenba) vaccine, composed of two factor H binding proteins (fHBPs), was recently licensed for the prevention of\n            <jats:italic>N.\u00a0meningitidis<\/jats:italic>\n            serogroup B (NmB) disease in individuals 10 to 25 years old in the United States. This study evaluated a large collection of NmB isolates from the United States and Europe by using a flow cytometric MEASURE assay to quantitate the surface expression of the vaccine antigen fHBP. We find that expression levels and the proportion of strains above the level associated with susceptibility in an hSBA are generally consistent across these geographic regions. Thus, the assay can be used to predict which NmB isolates are susceptible to killing in the hSBA and therefore is able to demonstrate an fHBP vaccine-induced bactericidal response. This work significantly advances our understanding of the potential for bivalent rLP2086 to provide broad coverage against diverse invasive-disease-causing NmB isolates.\n          <\/jats:p>","DOI":"10.1128\/mbio.00036-18","type":"journal-article","created":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T12:37:02Z","timestamp":1520858222000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":67,"title":["Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine"],"prefix":"10.1128","volume":"9","author":[{"given":"Lisa K.","family":"McNeil","sequence":"first","affiliation":[{"name":"Pfizer Vaccine Research and Development, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G. K.","family":"Donald","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research and Development, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Gribenko","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research and Development, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"French","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research and Development, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Lambert","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research and Development, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon L.","family":"Harris","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research and Development, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Jones","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research and Development, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Zlotnick","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research and Development, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Vogel","sequence":"additional","affiliation":[{"name":"Institute for Hygiene and Microbiology, University of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Claus","sequence":"additional","affiliation":[{"name":"Institute for Hygiene and Microbiology, University of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Abad","sequence":"additional","affiliation":[{"name":"Reference and Research Laboratory for Vaccine Preventable Bacterial Diseases, Institute of Health Carlos III, Majadahonda, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio A.","family":"Vazquez","sequence":"additional","affiliation":[{"name":"Reference and Research Laboratory for Vaccine Preventable Bacterial Diseases, Institute of Health Carlos III, Majadahonda, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[{"name":"Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Findlow","sequence":"additional","affiliation":[{"name":"Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0716-3174","authenticated-orcid":false,"given":"Muhamed-Kheir","family":"Taha","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Invasive Bacterial Infections Unit, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala-Eddine","family":"Deghmane","sequence":"additional","affiliation":[{"name":"Institut Pasteur, Invasive Bacterial Infections Unit, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique A.","family":"Caugant","sequence":"additional","affiliation":[{"name":"Department of Bacteriology and Immunology, Norwegian Institute of Public Health, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Kriz","sequence":"additional","affiliation":[{"name":"National Institute of Public Health, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Musilek","sequence":"additional","affiliation":[{"name":"National Institute of Public Health, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"Meningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeni","family":"Vuong","sequence":"additional","affiliation":[{"name":"Meningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard W.","family":"Mayer","sequence":"additional","affiliation":[{"name":"Meningitis and Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Pride","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research and Development, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin U.","family":"Jansen","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research and Development, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliesa S.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research and Development, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2006.00051.x"},{"key":"e_1_3_3_3_2","first-page":"E116","article-title":"Epidemiology of Neisseria meningitidis infections: case distribution by age and relevance of carriage","volume":"56","author":"Gabutti G","year":"2015","unstructured":"Gabutti G, Stefanati A, Kuhdari P. 2015. Epidemiology of Neisseria meningitidis infections: case distribution by age and relevance of carriage. J Prev Med Hyg 56:E116\u2013E120.","journal-title":"J Prev Med Hyg"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00056-12"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105033441807"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90340-9"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.071"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/126.5.514"},{"key":"e_1_3_3_9_2","first-page":"116","volume-title":"Identification of a novel vaccine candidate for group B Neisseria meningitidis","author":"Bernfield L","year":"2002","unstructured":"Bernfield L, Fletcher LD, Howell A, Farley JE, Zagursky R, Knauf M, Zlotnick G. 2002. Identification of a novel vaccine candidate for group B Neisseria meningitidis, p 116. In Caugant DA, Wedege E (ed), Abstracts of the Thirteenth International Pathogenic Neisseria Conference. National Institute of Public Health, Oslo, Norway."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.4.2088-2100.2004"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.12.7566"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31829aa63b"},{"key":"e_1_3_3_13_2","first-page":"103","article-title":"Predicted strain coverage of a new protein-based meningococcal vaccine in the Czech Republic","volume":"63","author":"K\u0159\u00ed\u017eov\u00e1 P","year":"2014","unstructured":"K\u0159\u00ed\u017eov\u00e1 P, Mus\u00edlek M, Vackov\u00e1 Z, Koz\u00e1kov\u00e1 J, Claus H, Vogel U, Medini D. 2014. Predicted strain coverage of a new protein-based meningococcal vaccine in the Czech Republic. Epidemiol Mikrobiol Imunol 63:103\u2013106.","journal-title":"Epidemiol Mikrobiol Imunol"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/600141"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70006-9"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.06.083"},{"key":"e_1_3_3_17_2","first-page":"5","article-title":"Trumenba: a serogroup B meningococcal vaccine","volume":"57","year":"2015","unstructured":". 2015. Trumenba: a serogroup B meningococcal vaccine. Med Lett Drugs Ther 57:5\u20136.","journal-title":"Med Lett Drugs Ther"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.01.021"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31827b0d24"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70087-7"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.07.065"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.051"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.34293"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001399"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1264750"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M808831200"},{"key":"e_1_3_3_27_2","first-page":"P137","volume-title":"LP2086 and MLST distribution in epidemiologically relevant strains of serogroup B Neisseria meningitidis","author":"Hoiseth SK","year":"2008","unstructured":"Hoiseth SK, Murphy E, Andrew L, Lee KL, Ambrose K, Dilts D, Borrow R, Findlow J, Taha MK, Deghmane AE, Kriz P, Musilek M, Kalmusova J, Caugant D, Alvestad T, Mayer L, Wang X, Zlotnick GW, Jansen KU, Anderson AS. 2008. LP2086 and MLST distribution in epidemiologically relevant strains of serogroup B Neisseria meningitidis, p P137. In van Alphen L, van der Lay P, van den Dobbelsteen G (ed), Abstracts of the Sixteenth International Pathogenic Neisseria Conference. National Institute of Public Health, Rotterdam, The Netherlands."},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/649209"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.04.092"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.16.1493"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.501"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1086\/424464"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.09.038"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.07.056"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1521142113"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.065"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.07.019"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.12.5939-5947.1998"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1101\/gr.664303"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.03134-14"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.01.066"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.01.075"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/bip.360100713"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(77)90043-4"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0507405102"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1232301100"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2836(03)00234-1"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0307204101"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.10069"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2013.06.033"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1385\/1-59259-148-5:289"},{"key":"e_1_3_3_52_2","unstructured":"World Health Organization Department of Vaccines and Biologicals. 1999. Standardization and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A\/C vaccines Geneva 8\u20139 March 1999. World Health Organization Geneva Switzerland. https:\/\/extranet.who.int\/iris\/restricted\/bitstream\/10665\/66298\/1\/WHO_V%26B_99.19.pdf."}],"container-title":["mBio"],"original-title":[],"contributor":[{"given":"Jan","family":"Poolman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"reviewer"}]},{"given":"Holly","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"reviewer"}]}],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mBio.00036-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mBio.00036-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T02:15:38Z","timestamp":1646705738000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/mBio.00036-18"}},"subtitle":[],"editor":[{"given":"Paul","family":"Dunman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,5,2]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,5,2]]}},"alternative-id":["10.1128\/mBio.00036-18"],"URL":"https:\/\/doi.org\/10.1128\/mbio.00036-18","relation":{},"ISSN":["2161-2129","2150-7511"],"issn-type":[{"value":"2161-2129","type":"print"},{"value":"2150-7511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,2]]},"assertion":[{"value":"2018-01-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00036-18"}}